budigalimab
1 product
6 abstracts
Abstract
First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.Org: START Midwest, Grand Rapids, MI, Memorial Sloan Kettering Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Yale School of Medicine, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Targeting GARP–TGF-β1 with livmoniplimab plus anti–PD-1 budigalimab to remodel the immunosuppressive tumor microenvironment.Org: North Chicago,
Abstract
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.Org: Weill Medical College at Cornell University, Liver Oncology and Therapeutic Innovation Unit, AP-HP-Hôpital Beaujon, Clichy, France, Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Department of Medicine, Section of Hematology and Oncology, University of Chicago,
Abstract
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.Org: Weill Medical College at Cornell University,
Abstract
Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.Org: Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, Universite Catholique De Louvain, Bruxelles, Belgium, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, VA New York Harbor Healthcare System, Manhattan Campus, New York, NY, Yonsei University Health System and Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.Org: Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Next Oncology Virginia and Virginia Cancer Specialists, AbbVie Inc., Sarah Cannon Research Institute at Tennessee Oncology, PLLC,
Product
Budigalimab